Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enecadin
- Development stage
- Discontinued
- Lead developer
- Paion
- Modality
- Small Molecules
01
Overview
Enecadin is a small molecule neuroprotective agent that acts as a voltage-dependent sodium and calcium channel blocker. It was primarily investigated for the treatment of acute ischemic stroke and other cerebrovascular accidents. Enecadin demonstrated efficacy in animal models of ischemic injury to the brain, spinal cord, and retina. Its mechanism involves blocking voltage-gated sodium channels (SCNA) and voltage-dependent calcium channels (VDCCs), as well as inhibiting calpain 1 (CAPN1) and calpain 2 (CAPN2). The drug reached phase II clinical development for stroke but was discontinued before approval. Enecadin was originally developed by Nippon Shinyaku, with later involvement from Paion Deutschland.
- Other names
- enecadin hydrochloride
02
Targets
CAPN (Schistosoma calpain large subunit family)NaV (Voltage-gated sodium channels)CaV (Voltage-gated calcium channel protein complex)
Beyond the preview
Go deeper on enecadin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enecadin.